Case Report

Prenatal Diagnosis of Adrenal Neuroblastoma: A Case Report with a Brief Review of the Literature

Onur Erol,1 Dinç Süren,2 and Melek Büyükkanaci Erol3

1 Department of Obstetrics and Gynecology, Antalya Education and Research Hospital, 07030 Antalya, Turkey
2 Department of Pathology, Antalya Education and Research Hospital, 07030 Antalya, Turkey
3 Department of Obstetrics and Gynecology, Medstar Hospital, 07030 Antalya, Turkey

Correspondence should be addressed to Onur Erol; dromurerol@hotmail.com

Received 15 February 2013; Accepted 12 March 2013

Academic Editors: B. A. Gbolade, A. Ohkuchi, and B. Piura

Copyright © 2013 Onur Erol et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

A case of adrenal cystic neuroblastoma detected at 37 weeks of gestation is reported. Postnatal ultrasonographic examination showed slightly increased in size demonstrating marked septations within the cyst. After the tumor was resected, histopathological examinations confirmed the diagnosis. The patient is developing normally at 1 year of age.

1. Introduction

Neuroblastoma is the most common solid tumor in children under 1 year of age [1]. The overall incidence is 58/1,000,000 infants per year [2]. This tumor is derived from neural crest cells, and it can arise anywhere in the sympathetic nervous system. Environmental factors or parental exposures that significantly impact on disease occurrences have been identified; also in 1-2% of cases there is a family history [3]. Specific tumor suppressor gene responsible for genetic abnormality in neuroblastoma has not been identified to date [4].

Prenatal diagnosis of neuroblastoma was first reported by Fénart et al. [5]. Neuroblastoma is normally diagnosed during the third trimester, and adrenal location is the most observed origin with a ninety percent. The prognosis depends on the extent of disease at diagnosis. Follow-up ultrasonographic examinations should be performed every two weeks from diagnosis to term in order to monitor the size of the mass and to detect antenatal metastatic complications [6].

We have reported a case of cystic adrenal neuroblastoma that was growing rapidly postnatally with a brief review of the literature.

2. Case Presentation

A 38-year-old woman, gravida 2 para 1, was referred to our center for assessment of cystic mass in fetal abdomen at 37 weeks of gestation. Her medical history was unremarkable. The detailed ultrasonographic evaluation revealed suprarenal cystic mass on the left side with a diameter of 45 * 45 mm (Figure 1). The cyst was homogenous with intracystic septations suggesting intracystic hemorrhage. Color Doppler imaging of the mass revealed peripheral vascularization, and no blood flow was seen in the cyst. The spleen and left kidney were normal in appearance. The possibility of neuroblastoma was raised. No other fetal structural abnormalities were observed. Maternal urine homovanillic acid and vanilmandelic acid levels were normal. Followup sonography two weeks later demonstrated the same size of cyst with an 8/8 score on the fetal biophysical profile. The infant was then delivered by cesarean section due to fetal malpositioning (breech presentation) at 39 weeks 4 days of gestation. A male infant weighing 3100 gram was born, with Apgar scores of 8 at 1 minute and 10 at 5 minutes. Postnatal sonographic examination confirmed the presence of an adrenal tumor measuring 48 * 50 mm in size. One week later cyst...
size was increased to $65 \times 70$ mm (Figure 2). Laparotomy was performed on the 8 day postpartum, and the tumor was resected. Histopathological examination of the tumor was consistent with well-differentiated neuroblastoma with tumor-free margins, and within intracystic hemorrhage was noted. Immunohistochemical staining for chromogranin-A, vimentin, CD99, and myogenin was negative with poorest staining for synaptophysin (Figure 3). Tumor cytogenetic analysis showed no aneuploidy. The infant had an uncomplicated postoperative course and was discharged 10 days later. He required no further treatment and remained free of disease 1 year later.

### 3. Discussion

Improvements in prenatal imaging and widespread use of fetal ultrasonography have led to an increased rate of prenatal diagnosis of fetal neuroblastoma. The features of neuroblastoma on the antenatal ultrasound are variable and range from cystic, mixed solid and cystic, and completely solid with or without calcification. Patients with cystic neuroblastoma had a better outcome than those noncystic tumors [7]. The main differential diagnosis is adrenal haemorrhage which is the most common cause of adrenal mass during the perinatal period with an incidence of 1, 9/1000 live births [8]. It is important to differentiate benign adrenal lesions like adrenal hemorrhage or adrenal cysts from neuroblastoma. Magnetic resonance imaging (MRI) is the modality of choice for differentiation between these situations and to detect early metastatic complication of neuroblastoma in the perinatal period. Other suprarenal masses like extralobular pulmonary sequestration, adrenal abscess, adrenal nodular hyperplasia, adrenal cyst, bronchogenic cyst, and rarely adrenal carcinoma may mimic neuroblastoma, so differential diagnosis from these circumstances must be considered [9].

Reported prevalence of neuroblastoma cases in prenatally detected suprarenal masses is 81–85% in the literature [10,11]. The entity “neuroblastoma in situ” represents the collections of neuroblastoma cells, and it is important to distinguish this from clinically apparent neuroblastoma [12]. Cystic neuroblastoma is thought to be a form of neuroblastoma in situ that is associated with highest survival rate of all forms of neuroblastoma [13]. These tumors are characterized by Shimada favorable histology and biological markers such as aneuploid DNA content, lack of chromosome 1p deletion, and absence of MYCN (myelocytomatosis viral related oncogene) amplification [14,15]. Conflicting correlation results between clinical course and biological markers are also stated in the literature [16,17].

Relationship between neuroblastoma and congenital heart defects was emphasized in a report with a recommendation of echocardiography for congenital cardiovascular malformation screening in patients with newly diagnosed neuroblastoma [18]. Fetal hypertension and heart failure, invasion of erythropoietic tissue with tumor cells, and metastasis to the placenta may lead to development of fetal hydrops [19].

Urinary catecholamines are helpful in confirming the diagnosis of neuroblastoma; however, they will be normal in two-thirds of patients with prenatally diagnosed tumors, thus this test will not serve as a reliable diagnostic aid in every case [20]. Evaluation for the presence of metastatic disease must be considered with MRI, computerized tomography (CT) scanning, or $^{123}$I methylidobenzylguanidine (MIBG) scintigraphy that is most sensitive for identifying metastases in general [10]. Classification according to the International Neuroblastoma Staging System (INSS) is a combined clinical/surgical staging system that includes local extension of the tumor, lymph node involvement, extent of resection of the primary tumor, and presence of distant metastatic disease [21]. The liver was the main site of metastases followed in
order by the bone marrow, skin, and lungs. Most prenatally
diagnosed neuroblastoma is adrenal tumors at favorable
stages (INSS stage I, II, or IV-S), and also rare region
like pancreatic, cervical neuroblastoma have been reported
[22, 23].

The treatment options for congenital neuroblastoma
include surgery, chemotherapy followed by surgery or expec-
tant management with ultrasonographic followup [24]. Most
patients with stages 1 and 2 disease can be cured with surgery
alone [15]. The use of chemotherapy is reserved for high stage
metastatic disease. The strategy of surgical exploration of
adrenal masses has been replaced by a wait and see strategy in
recent years in low stage neuroblastoma [8]. Tumour regres-
sion in 11 of 12 cases of early stage neuroblastoma detected by
mass screening was reported [25]. Dumbbell neuroblastoma
is considered to be unresectable tumor, and preoperative
chemotherapy is recommended [26]. The treatment is often
followed by excision of the tumor.

4. Conclusion

Close sonographic monitoring of cystic adrenal masses dur-
ing the first months life is helpful to detect early complica-
tions, and surgical excision could be performed safely during
the neonatal period.

Consent

A consent has been obtained from the patient for the
publication of this paper and the accompanying images.

Conflict of Interests

No conflict of interests was declared by the author.

References

System Tumors (ICCC IV),” in Cancer incidence and survival
among children and adolescents: United states SEER Program
pp. 65–72, National Cancer Institute, SEER Program, Bethesda, Md,
USA, 1999.


predisposition to neuroblastoma does not map to chromosome

toma,” Journal of Clinical Oncology, vol. 17, no. 7, pp. 2264–2279,
1999.

“Retropertitoneal neuroblastoma diagnosed in utero. Apropos of

outcome of neuroblastoma detected before birth,” Journal of

review of 271 cases,” Fetal and Pediatric Pathology, vol. 26, no. 4,

haemorrhage—two-dimensional and three-dimensional imag-

diagnosis of fetal bilateral adrenal carcinoma,” Ultrasound

localized masses diagnosed during the perinatal period: a
retrospective multicenter study,” Cancer, vol. 94, no. 9, pp. 2474–
2480, 2002.

features and surgical outcome of a suprapelvic mass detected

contribution to the natural history of neural crest tumors,” The

et al., “Cystic neuroblastoma: emphasis on gene expression,
morphology, and pathogenesis,” Pediatric and Developmental

roblastoma Pathology Classification for prognostic evaluation
of patients with peripheral neuroblastic tumors: a report from
the Children’s Cancer Group,” Cancer, vol. 92, no. 9, pp. 2451–

variables in the outcome of stages I and II neuroblastoma
accepted with surgery as primary therapy: a Children’s Cancer
Group study,” Journal of Clinical Oncology, vol. 18, no. 18, pp. 18–
26, 2000.

lastoma in the newborn. A study of the Italian Neuroblastoma
Registry,” European Journal of Cancer, vol. 45, no. 18, pp. 3220–
3227, 2009.

outcome of infants with metastatic neuroblastoma: MYCN
amplification and/or bone lesions: results of the French Society
of Pediatric Oncology,” British Journal of Cancer, vol. 83, no. 8,

[18] R. E. George, S. E. Lipshtultz, S. R. Lipsitz, S. D. Colan,
and L. Diller, “Association between congenital cardiovascular
malformations and neuroblastoma,” Journal of Pediatrics,

resulting from metastatic congenital neuroblastoma,” Inter-


international criteria for neuroblastoma diagnosis, staging, and
response to treatment,” Journal of Clinical Oncology, vol. 11,

[22] H. R. Kumar, J. A. Sandoval, M. A. Lovell, L. Z. Fenton, and J. F.
Bealer, “Primary pancreatic neuroblastoma: an unusual tumor
646, 2010.


Submit your manuscripts at http://www.hindawi.com